Document is current

Any future updates will be listed below

Correction: Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn’s Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?

Crossref DOI link: https://doi.org/10.1007/s41669-026-00648-9

Published Online: 2026-04-21

Published Print: 2026-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark